ACXP - Acurx stock plunges 26% amid Phase 2 data release for C. diff drug
2024-01-17 11:49:53 ET
More on Acurx Pharmaceuticals
- Acurx Pharmaceuticals, Inc. (ACXP) Q3 2023 Earnings Call Transcript
- Acurx Undervalued And Set For Potential M&A With Next-Gen C. Diff Treatment
- ELAB, KIND and RLX among pre-market losers
- Acurx spikes after mid-stage data for oral antibiotic
- Seeking Alpha’s Quant Rating on Acurx Pharmaceuticals
For further details see:
Acurx stock plunges 26% amid Phase 2 data release for C. diff drug